Another CRC-related gene, SEPT9, is commonly detected in the plasma of patients with primary CRC and was submitted to the FDA for marketing application in 2010 as a molecular marker for early clinical stage CRC. The gene discussed is SEPTIN9; the disease is colorectal carcinoma.